# HiberCell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hibercell

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.hibercell.com
- Total disclosed funding: $110M
- Latest round: Series B (May 19, 2021)
- Investors on record: 11

## About

HiberCell, Inc. is a biotechnology company dedicated to developing innovative cancer therapeutics that address treatment resistance, relapse, and metastasis through targeted mechanisms.Founded in 2019, HiberCell, Inc. is headquartered in New York, US. The company focuses on developing therapies to combat cancer treatment challenges. Co-founded by Alan Rigby and Julio Aguirre-Ghiso, HiberCell has completed 4 deals and raised a total of USD 67.40 mn, with the latest round being a Venture Debt round led by Hercules Capital amounting to USD 30.00 mn.HiberCell specializes in innovative cancer therapeutics aimed at treating resistant cancers. Its primary offerings include HC-7366, which activates the GCN2 kinase, and HC-5404, targeting the PERK pathway in cancer cells. Additionally, the company is developing Odetiglucan, which enhances anti-cancer immune responses. These products primarily cater to healthcare providers and pharmaceutical partners across North America and Europe.HiberCell's revenue is generated through partnerships with pharmaceutical companies and research institutions focused on cancer therapeutics. Their business model includes licensing agreements, milestone payments, and royalties on future product sales, linked to clinical developments of HC-7366 and HC-5404, which are critical to their pipeline.HiberCell plans to leverage its recent funding to support the advancement of its therapeutic candidates and facilitate entry into new markets, particularly in Europe and Asia by 2024. The company is focused on launching new products designed to address critical oncology challenges, enhancing its market presence and therapeutic offerings as it progresses through clinical trials.

## Funding rounds

- Series B, May 19, 2021, $67M — ARCH Venture Partners, Tekla Capital Management, Bristol-Myers Squibb Company, Monashee Investment Management, Trinitas Capital, Huizenga Capital Management, Magnetic, Mount Sinai Innovation Partners
- Series A, Feb 7, 2019, $43M — ARCH Venture Partners, Hillhouse Investment, 6 Dimensions Capital, Bristol-Myers Squibb Company, NYC Life Sciences Fund

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series A
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series A
- Bristol-Myers Squibb Company — Series A, Series B
- NYC Life Sciences Fund — Series A
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series B
- Monashee Investment Management — Series B
- Trinitas Capital (https://capitalatlas.ai/funds/trinitas-capital) — Series B
- Huizenga Capital Management (https://capitalatlas.ai/funds/huizenga-capital-management) — Series B
- Magnetic (https://capitalatlas.ai/funds/magnetic) — Series B
- Mount Sinai Innovation Partners (https://capitalatlas.ai/funds/mount-sinai-innovation-partners) — Series B